Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval

PURPOSE: Adjuvant pertuzumab and neratinib are independently FDA-approved for treatment of early-stage HER2-positive breast cancer in combination with or following trastuzumab for one year, respectively. Both agents reduce the risk of recurrence; however, the absolute benefit is modest for many pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Stoen, Ericson, Kagihara, Jodi, Shagisultanova, Elena, Fisher, Christine M., Nicklawsky, Andrew, Kabos, Peter, Borges, Virginia F., Diamond, Jennifer R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197701/
https://www.ncbi.nlm.nih.gov/pubmed/33625615
http://dx.doi.org/10.1007/s10549-021-06132-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197701/
https://www.ncbi.nlm.nih.gov/pubmed/33625615
http://dx.doi.org/10.1007/s10549-021-06132-8

Ejemplares similares